Heterozygous coding mutations in the INS gene that encodes preproinsulin were recently shown to be an important cause of permanent neonatal diabetes. These dominantly acting mutations prevent normal folding of proinsulin, which leads to beta-cell death through endoplasmic reticulum stress and apoptosis. We now report 10 different recessive INS mutations in 15 probands with neonatal diabetes. Functional studies showed that recessive mutations resulted in diabetes because of decreased insulin biosynthesis through distinct mechanisms, including gene deletion, lack of the translation initiation signal, and altered mRNA stability because of the disruption of a polyadenylation signal. A subset of recessive mutations caused abnormal INS transcription, including the deletion of the C1 and E1 cis regulatory elements, or three different single base-pair substitutions in a CC dinucleotide sequence located between E1 and A1 elements. In keeping with an earlier and more severe beta-cell defect, patients with recessive INS mutations had a lower birth weight (−3.2 SD score vs. −2.0 SD score) and were diagnosed earlier (median 1 week vs. 10 weeks) compared to those with dominant INS mutations. Mutations in the insulin gene can therefore result in neonatal diabetes as a result of two contrasting pathogenic mechanisms. Moreover, the recessively inherited mutations provide a genetic demonstration of the essential role of multiple sequence elements that regulate the biosynthesis of insulin in man.
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gene regulation | genetic testing | gene expression regulation | RNA instability | promoter regions N eonatal diabetes is diagnosed within the first 6 months of life (1, 2) and there are two main clinical subtypes: the persistent, permanent neonatal diabetes (PNDM) and the remitting and frequently relapsing, transient neonatal diabetes (TNDM). Recently there have been considerable advances in the understanding of the genetics of neonatal diabetes (3) . Most patients with PNDM have activating mutations in KCNJ11 or ABCC8, the genes encoding the potassium ATP-sensitive (K ATP ) channel subunits Kir6.2 (4) and SUR1 (5-7), or heterozygous mutations in the preproinsulin (INS) gene (8) (9) (10) (11) (12) . In contrast, abnormalities in chromosome 6q24 are the most common cause of TNDM (13) , followed by mutations in the KCNJ11 and ABCC8 genes (14) . Despite these advances, the etiology of neonatal diabetes is still not known in at least 30% of patients with PNDM, suggesting other genetic causes are still to be found (9) .
Insulin is secreted from islet beta cells of the pancreas. Insufficient secretion of insulin results in hyperglycemia and diabetes, whereas excessive secretion results in hypoglycemia. Insulin biosynthesis and secretion are therefore tightly regulated to maintain blood glucose levels within a narrow physiological range. Extensive studies have dissected an array of cis sequence elements in the INS promoter region and their cognate DNA binding factors, which together ensure the cellular specificity and rate of INS transcription (15) (16) (17) (18) (19) (20) (21) (22) . In addition, insulin biosynthesis is strongly dependent on posttranscriptional regulatory mechanisms, including the modulation of translation and stability (23) (24) (25) . The latter is largely mediated through sequences located in the untranslated regions of INS transcripts (26) (27) (28) .
Heterozygous missense mutations in the coding region of the INS gene have recently been described as a cause of neonatal diabetes (8) (9) (10) (11) (12) . Most of the reported mutations are predicted to disrupt the folding of the proinsulin molecule. The resulting misfolded protein accumulates in the endoplasmic reticulum (ER), resulting in ER stress and beta-cell apoptosis (29, 30 ). An alternative potential genetic mechanism would be reduced insulin secretion because of a disruption of the INS coding sequence, as seen in the double Ins1 and Ins2 knockout mouse (31) , or of the sequences that regulate insulin biosynthesis. However, as yet this has not been demonstrated in humans.
We now report recessively acting mutations within the INS gene in a series of patients with neonatal diabetes. In contrast to the previously described dominant mutations, these mutations reduce insulin synthesis and thus represent a unique pathogenic mechanism for human diabetes. These mutations also provide genetic evidence for the essential role of distinct nucleotide sequences in the regulation of the human preproinsulin gene.
Results
Recessive INS Mutations Cause Neonatal Diabetes. We sequenced 117 unrelated probands with diabetes diagnosed before 6 months (13 offspring of consanguineous parents) in whom the known common genetic causes had been excluded. We The mutations were inherited in a recessive manner either homozygous or compound heterozygous, with heterozygous carrier parents being unaffected with neonatal diabetes (Fig. 2) . Pathogenicity of mutations was suggested by conservation across species and absence of variants in controls (Table S1 ).
Recessive INS Mutations Uncover Essential Regulatory Sequences in
Humans. Further support for the pathogenicity of mutations came from known function of mutated residues and functional studies (Figs. 3 and Figs. 4 ; see also SI Results). Multiple mutation mechanisms were involved in the recessive INS mutations, which are described briefly below. Truncated proteins. The nonsense mutation (p.Q62X) is predicted to give rise to a mutant protein that is truncated within the Cpeptide region and will lack the insulin-A chain. Promoter mutations. The (c.-366_-343del) 24-base pair deletion abolishes the INS promoter evolutionary conserved C1 and E1 elements, where MAFA and NEUROD1 bind, respectively (16, 20, 32) (Fig. 3A) . The c.-218A > C mutation disrupts the CRE3 site that interacts with multiple DNA binding proteins in vitro (22) (Fig. 3A) . All of these elements have been previously shown to be critically important for the INS promoter activity in transient transfection studies (15, 18, (33) (34) (35) . The c.-331(C > G, C > A) and c.-332C > G mutations were located between the E1 and A1 elements (Fig. 3A) . This sequence is conserved among a subset of mammalian species (Fig. 3A) and mutagenesis of multiple bases neighboring this dinucleotide impairs INS promoter activity (36) . We constructed insulin promoter fragments carrying the point mutations c.-331(C > G, C > A) and c.-332C > G. The point mutations induced up to 90% reduction in transcriptional activity, while a control mutation, c.-339G > A, did not alter the transcriptional activity in pancreatic beta-cell lines (Fig. 3B) . Thus, the CC dinucleotide that is mutated in eight unrelated probands with neonatal diabetes forms part of an essential positive cis regulatory sequence of the INS promoter. Mutated or absent translational start site. The two point mutations (c.3G > A and c.3G > T) at the first methionine residue (p.Met1) abolish the native translation initiation site for the preproinsulin protein. Quantification of total INS mRNA levels by real-time PCR revealed no differences in mRNA abundance for c.3G > A or c.3G > T mutations compared with the wild type. The insulin content of HeLa cells transfected with these mutations was reduced by 86% and 79% for c.3G > A and c.3G > T, respectively, compared to cells transfected with the wild-type sequence ( Fig. 4A and SI Results). The multiexon deletion (exons 1 and 2) removes over half the coding region including the translational start site and is expected to be a null mutation.
Altered mRNA stability through a mutation in the 3′ untranslated region.
The c.*59A > G mutation is located in the polyadenylation signal of the 3′ untranslated region and potentially impairs mRNA stability. In a heterozygous lymphoblastoid cell line generated from the proband's mother, the mutant mRNA transcript was present at a very low level compared to the wild-type allele. This is consistent with reduced mRNA stability ( Table 1 (Table S1 and S2). In keeping with the known actions of insulin before and after birth, the phenotype was limited to markedly reduced fetal growth and diabetes.
The diabetes phenotype within the families is shown in Fig. 2 . Nineteen patients had neonatal diabetes (15 probands and 4 family members); 14 had PNDM and were treated with insulin from diagnosis, and 5 patients had TNDM, having gone into remission at a median age of 12 weeks [interquartile range (IQR) 11, 22] . Birth weight was markedly reduced in all patients with neonatal diabetes resulting from recessive mutations [median birth weight 1,680 g (1,420; 2,050), which is −3.2 SD score (−4.1, −2.6)]. In keeping with more severe insulin deficiency, patients with PNDM had a more severe intrauterine growth retardation [median SD score for birth weight −3.9 (−4.4, −2.8) vs. −1.8 (−3.4, −0.9) in TNDM, P = 0.03] and diabetes was diagnosed earlier [2 days (1, 9.5) vs. 24 days (5, 62), P = 0.04] (Table S3 ). All patients with mutations that altered the coding region or mRNA stability had PNDM. The noncoding promoter mutations were associated with both PNDM and TNDM. A summary of the remaining 98 patients with neonatal diabetes of unknown origin is given in Table S4 . . TNDM is only seen in patients with recessive mutations (26 vs. 0%, P = 0.001). Overall, recessive INS mutations accounted for 3.7% PNDM (n = 300) and 2.2% TNDM (n = 134) in a consecutive series of patients with isolated neonatal diabetes referred to the two laboratories for genetic testing.
Discussion
We have shown that recessively acting mutations in the preproinsulin gene (INS) are a cause of neonatal diabetes. They act by reducing synthesis of the preproinsulin peptide because of a truncated protein, abnormal transcription, reduced mRNA stability, or disrupted translation. These mutations usually cause PNDM but may manifest as TNDM or diabetes outside the neonatal period. In keeping with the recessive inheritance, many probands (60%) were the offspring of consanguineous parents.
The clinical manifestations of recessive INS mutations reflect the consequences of insulin deficiency in humans during pre-and postnatal life. The birth weight was markedly reduced [median SD score −3.2 (−4.1, −2.6)], consistent with the major role of insulin in fetal growth. The early onset of neonatal diabetes (median 1 week) reflects severe insulin deficiency postnatally. In contrast to many other subtypes of neonatal diabetes, there are no extrapancreatic features.
Differences in the underlying pathophysiology explain why patients with recessive INS mutations are diagnosed earlier and have a lower birth weight than patients with heterozygous INS mutations (8) (9) (10) (11) (12) . The disrupted insulin synthesis seen with recessive mutations occurs as soon as the fetal beta cell starts to secrete insulin. In contrast, insulin secretion is required before beta-cell dysfunction develops in patients with heterozygous mutations, which result in misfolding of the preproinsulin peptide, accumulation of the misfolded protein in the ER, and hence the destruction of the beta cell through ER stress. These two distinct disease mechanisms are supported by phenotypic studies in mouse models, where reduced insulin secretion at birth or progressive ER stress and cell death have been described in mice carrying analogous recessive or dominant mutations, respectively (30, 31, 37) .
The majority of the patients with neonatal diabetes have PNDM, but 26% (5 of 19) have TNDM. TNDM is only found in patients with noncoding mutations and they have a higher birth weight and are diagnosed later. This finding is consistent with TNDM resulting from a less severe insulin deficiency, and is comparable to the situation with mutations in the Kir6.2 subunit of the K ATP mutations (38) , where TNDM mutations have less severe functional consequences. The mechanism of remission in recessive INS mutation carriers is not understood but is likely to reflect a variation in demand or the ability of the beta cell to meet this demand, as a similar timing of remission is seen in some patients with less severe mutations, resulting in channelopathies (14, 38) and pancreatic developmental defects (39, 40) .
The mutations identified in this study illustrate multiple mechanisms by which insulin biosynthesis can be disrupted. These include absent or altered translation because of coding-sequence deletions or mutations, reduced transcription because of mutations of the promoter, or abnormal mRNA stability. Our functional studies established that the 3′ UTR mutation that abolishes the polyadenylation signal results in severe RNA instability and that the initiation codon mutations result in reduced transcription of the preproinsulin gene. The promoter mutations are highly informative because they provide human genetic evidence that discrete INS cis regulatory elements are essential. Numerous studies have demonstrated that multiple cis elements are required for the activity of episomal INS reporter constructs in cultured cells (15, 17-19, 21, 22) . However, it is not known if each of those cis elements is truly necessary in vivo, because such studies can only partially predict their function in the integrated chromatin environment of bona fide differentiated cells. Studies in other selected genes have addressed this by targeted deletion of transcriptional regulatory elements in mice (41) . Our findings now reveal that the C1/E1, CC, and CRE3 elements are essential for INS gene transcription in humans. The discovery of three separate mutations that target the CC dinucleotide sequence is particularly significant. This element forms part of a canonical CCACC binding-site motif for Kruppel-like zinc-finger proteins. Two recent studies have shown that artificial mutations of this CCACC element lead to decreased INS promoter activity (36, 42) . Although previous studies failed to identify protein complexes interacting with this region in beta-cell nuclear extracts (17, 36) , a recent study showed that in vitro translated GLIS3, a zinc-finger transcription factor that is mutated in patients with neonatal diabetes and congenital hypothyroidism (43) , exhibits sequence-specific binding to this region (42 367_-344del (-129_-106) c. bind to CCACC elements in vitro, and thus future studies are warranted to determine if additional factors act through this element in vivo in beta cells. Our findings, therefore, demonstrate that the natural CC element mutations that cause diabetes disrupt INS gene activity and establish the importance of this cis regulatory element.
In conclusion, we have shown that homozygous INS mutations are a unique cause of neonatal diabetes. The mutations result in reduced synthesis of the insulin polypeptide through a variety of mechanisms and may yield further insights into the regulation of insulin biosynthesis.
Materials and Methods
Cohort Characteristics. We studied an international cohort of 117 unrelated patients (67 males) with diabetes diagnosed before 6 months (median age 4 weeks) and without a known genetic etiology, which were referred to the Exeter (n = 105) or Bilbao laboratories (n = 12). Thirteen patients were offspring of consanguineous parents (second-degree relatives or closer). In the 100 probands with PNDM, we excluded mutations in KCNJ11, ABCC8, GCK, and previously described heterozygous coding mutations in INS (9). In the 17 patients with TNDM, we excluded 6q24 anomalies, KCNJ11, and ABBC8 mutations. Remission was defined as the disappearance of clinical symptoms with normalization of blood glucose or HbA1c for a period longer than 15 days after withdrawal of insulin therapy. Babies born before 33 weeks of gestation were excluded to avoid hyperglycemia of prematurity. Studies were approved by Cruces Hospital committee and North and East Devon Research Ethics Committee. Informed consent was obtained from all patients or their parents and the studies were conducted in line with the Declaration of Helsinki. Clinical data were obtained from the patients' clinical records. We calculated standard deviation scores for birth weight (44) .
Molecular Genetic Analysis. Genomic DNA was extracted from peripheral leukocytes using standard procedures. Regulatory elements up to 450 bp upstream of the transcriptional start site and exons 1 to 3 of the INS gene (Fig.  1) were amplified by the PCR in three amplicons (primers and conditions available on request). Unidirectional sequencing was carried out on an ABI3730 (Applied Biosystems) and analyzed using Mutation Surveyor v3.20. Sequences were compared with the published sequence (Ensembl sequence ENSG00000129965) and published polymorphisms. The genomic reference sequence nucleotide 1 is the transcriptional start site (g.1A or c.-238A), whereas the translational start site is located at g.238 (c.1). Mutation nomenclature is shown in compliance with the Human Genome Variation Society, where nucleotide 1 represents the A of the translational start-site codon ATG (c.1). Suspected mutations were tested for conservation across species and cosegregation within families. Putative gene deletions were investigated using multiplex ligation-dependent probe amplification assay oligonucleotide probes specific for the three exons of INS (see SI Materials and Methods).
Functional Studies. Investigating the effect of INS promoter mutations on transcriptional activity. To determine the functional impact of the c.-331(C > G, C > A) and c.-332C > G mutations we performed site-directed mutagenesis of an INS promoter firefly luciferase reporter construct (pSOUAPRL-251hINS-Luc), and compared the activity of control and mutated promoters in MIN6 β-cells, using a Renilla luciferase promoter (pGL4.75) to correct for differences in transfection efficiency (see SI Materials and Methods). Investigating the effect of the translation initiation mutations (c.3G > T and c.3G > A). To determine the effect of these mutations on insulin production, we transfected HeLa cells, which do not express insulin, with wild-type or mutant INS and analyzed intracellular insulin content using radio-immunoassay (SI Materials and Methods). Investigating the effect of the c.*59A > G mutation on mRNA stability. We determined the effect of the c.*59A > G mutation on insulin mRNA stability using real time PCR to measure the relative levels of the INS mRNA transcripts in a heterozygous lymphoblastoid cell line derived from the proband's mother. We used a heterozygous SNP, rs3842753, to identify the mutation bearing allele (SI Materials and Methods).
Statistical Analysis. Clinical numeric data are given as median (IRQ range). Functional data are given as mean (SE). The clinical features of patients were compared using Kruskal-Wallis, χ 2 (Fisher's exact) tests or Mann-Whitney U in the statistical package SPSS version 13. Student's t-test or analysis of variance was used for expression studies. , and thus the experimental error is not visible in the figure. To investigate the possibility of low levels of translation from p. Met5, we used an in vitro radio-immunoassay to measured insulin content in cells expressing the mutations compared to cells expressing wild type (WT) INS. The cells expressing INS (WT) contained 56 pg of insulin per million cells, while the insulin content was reduced by at least 79% in the cells expressing INS c.3G > T and c.3G > A (11.9 and 7.6pg of insulin per million cells respectively) (Fig. 4A) . These data show that p.Met5 is unlikely to reinitiate translation of preproinsulin in the presence of the c.3G > T or c.3G > A mutations.
Effect of the c.*59A > G Mutation on RNA Stability. To investigate the effect of the c.*59A > G mutation on RNA stability we used real-time PCR to quantify the level of INS mRNA transcripts in a heterozygous lymphoblastoid cell line generated from the proband's mother (DM1165). We were unable to discriminate between the transcripts directly via the c.*59A/G alleles, as the mutation was located at the far 3′ end of the transcript. Instead, we used a SNP (rs3842753) to tag the mutation, with the mutation (c.*59G) on the same haplotype as the C allele of the SNP. The mutation-bearing transcript was not detectable in the heterozygous mother (Fig. 4B) and in the homozygous state we predict that the affected child will not express the INS gene.
SI Materials and Methods
Gene-Dosage Analysis Using MLPA. We designed MLPA assay oligonucleotide probes (sequences available on request) to measure the number of copies of INS exons 1 to 3 using probes for HNF1A and HNF4A as controls (method previously described by ref.
2).

Methodology for the Investigation of the Effect of Promoter
Mutations on Insulin Gene Promoter Activity. A plasmid containing nucleotides c.-489 to c.-228 of the human insulin gene promoter (pSOUAPRL-251hINS-Luc) linked to the firefly luciferase gene (Roland Stein, Vanderbilt University) was used to perform sitedirected mutagenesis with the QuikChange kit (Stratagene). Three independent clones were created for each base substitution. The plasmids were verified by direct sequencing, and assayed in transient transfection assays in triplicate on three separate occasions, as described (3). MIN6 β cells were trypsinized 24 h before transfection, plated into 24-well plates (1 × 10 5 cells per well) and maintained in DMEM supplemented with 15% FBS, 2 mM Glutamine, and 50 nM 2-Mercaptoethanol. Cells were transfected with promoter-luciferase constructs (500 ng) using Metafectene PRO (Biontex), following manufacturers instructions. pGL4.75[hRluc/ CMV] (10 ng) was included in the transfections to normalize for transfection efficiency. Twenty-four hours posttransfection, Firefly and Renilla luciferase activity was assayed using Dual-Luciferase Reporter Assay System (Promega), and the ratios were expressed relative to the wild-type insulin promoter values. Noninsulin expressing HeLa cells were cultured in DMEM Glutamax medium (Gibco Life Technologies) supplemented with 5% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin at 37°C in a fully humidified atmosphere of 5% CO 2 .
To rule out an effect of these mutations on mRNA stability, we quantified the amount of INS mRNA relative to the Beta-2-microglobulin (B2M) gene in transfected cells. Total RNA was extracted from ≈1 × 10 6 HeLa cells using the Perfect RNA Mini RNA kit (Eppendorf). Next, 4.5 μg mRNA was treated with 2 units of RNase-free DNase (TURBO DNase kit, Ambion) to remove Genomic DNA by following the manufacturer's instructions. cDNA was synthesized from mRNA using the Thermoscript RT-PCR system (Life Technologies) with an incubation temperature of 50°C and a random hexamer primer. PCR products were detected by the use of a probe situated across the boundary of exons 2 and 3 to ensure amplification from cDNA rather than genomic DNA (forward primer; CGGGAGGCAGAGGACCT, reverse primer; AGGCTGCCTGCACCAG, probe; 6FAM-AC-CTGCCCCACCTGC-MGB). Reactions contained 5-μL TaqMan Fast Universal PCR Master Mix, no AmpErase, 0.9 μM each primer and 0.25 μM probe in a total volume of 10 μL on the ABI prism 7900HT platform (Applied Biosystems). Amplification conditions were a single cycle of 95°C for 20 s followed by 60 cycles of 95°C for 1 s, and 60°C for 20 s. The results given are an average of quantifications from three replicate amplifications.
Expression levels of the mutant and wild-type transcripts were measured by comparing the number of cycles at which the INS and B2M PCR products cross a specific threshold. The relative abundance is defined by the difference in number of cycles to achieve the same quantity of product and calculated using the equation 2 −ΔΔCt , where ΔΔCt is the difference between the crossing points (ΔCt test ) in a test sample normalized to a reference sample (ΔCt ref ) (Applied Biosystems). Differences in the mRNA abundance for wild-type and mutant transcripts were examined for statistical significance by Kruskal-Wallis test.
The insulin content of transfected HeLa cells was determined 24 h posttransfection by radio-immunoassay. Briefly, cells were lysed in 200 μL of acidified ethanol (0.8 M HCl:98% ethanol mixed in a ratio of 1:3) for 2 h at −20°C and samples then neutralized by addition of NaOH. In triplicate, 50 μL of each experimental sample or crystalline recombinant human insulin standard was mixed with 50 μL of 125 I insulin (Linco; diluted to yield ≈2,000 cpm/50 μL) and 50 μL Guinea Pig anti-bovine insulin antibody (ICN) diluted 1:20,000 in insulin assay buffer (IAB; 150 mM NaCl, 30 mM Na 2 HPO4, 10 mM KH 2 PO 4 , 10 mM EDTA, 5 mg/mL BSA, pH 7.4). Tubes were incubated at 4°C overnight before addition of 50 μL of donkey anti-Guinea Pig coated cellulose beads (IDS Ltd.) (diluted 1:1 with IAB). After incubation for 1 h, 2-mL dH 2 O was added and tubes centrifuged for 5 min at 1,000 × g. The supernatant was aspirated under vacuum and the radioactivity retained in each pellet measured on a WALLAC gamma counter. The insulin content of each sample was then calculated by reference to a standard curve constructed with recombinant human insulin. Total RNA was extracted from ≈1 × 10 6 EBV-transformed lymphoblastoid cells using the Perfect RNA Mini RNA kit (Eppendorf). Next, 4.5 μg mRNA was treated with 2 units of RNase-free DNase (TURBO DNase kit, Ambion) 30 min at 37°C followed by 85°C for 5 min for nuclease inactivation. CDNA (cDNA) was synthesized from mRNA using the Thermoscript RT-PCR system (Life Technologies) with an incubation temperature of 50°C and a random hexamer primer.
Ectopic mRNA transcripts were amplified from lymphoblastoid cells using a single tube TaqMan approach. It was not possible to design probes for the c.*59A > G mutation because of its location at the extreme 3′ end of the transcript. Instead we used a heterozygous single nucleotide polymorphism (rs3842753) located 37 nucleotides upstream of the poly-A tail to differentiate the mutation-bearing and normal transcripts. Probe and primer sequences were designed to this variant and validated by standard curve analysis [Forward -5′ ggagaactactgcaactagac 3′, Reverse -5′ catctctctcggtgcaggag 3′, Probe (WT) -VIC-cagccccAcacccg-MGB, Probe (MT) -6-FAM-agccccCcacccg-MGB].
Two microliters cDNA from the proband's mother (heterozygous for c.*59A > G and rs3842753) was used for real-time PCR quantification and cDNA from a normal cell line (heterozygous for rs3842753 only). PCR products were detected by the use of mutation-specific probes which were identical except for the site of the mutation. Reactions contained 5-μL TaqMan Fast Universal PCR Master Mix, no AmpErase, 0.36 μM each primer, and 0.08 μM each probe in a total volume of 10 μL on the ABI prism 7900HT platform (Applied Biosystems). Amplification conditions were a single cycle of 95°C for 20 s, followed by 60 cycles of 95°C for 1 s, and 60°C for 20 s. The results given are an average of quantifications from three triplicate amplifications derived from two separate RNA extractions.
To validate the real-time assay, we conducted standard curve analysis, which indicated that the assay was accurate and quantitative over seven serial 1:2 dilutions. The efficiency of amplification as assessed by the gradient of the standard curves for mutant and wild-type probes were −3.1 and −3.0, respectively. The correlation between crossing point and input template (r 2 ) was 0.95 and 0.92 for the mutant and wild-type probes, respectively. The A-and C-allele transcripts of rs3842753 are present in approximately equal amounts in the normal heterozygous cell line, indicating that the presence of this SNP does not adversely affect the stability of either allele.
Expression levels of the mutant and wild-type transcripts were measured using the allele-specific assays by comparing the number of cycles at which the two different PCR products cross a specific threshold. The relative abundance is defined by the difference in number of cycles to achieve the same quantity of product and calculated using the equation 2 −ΔΔCt , where ΔΔCt is the difference between the crossing points [(ΔCt test ) in a test sample normalized to the difference between mutant and normal crossing points in a 50:50 mixture (ΔCt 50% ) (Applied Biosystems (4)]. All mutations are homozygous except for DM 1265, which is compound heterozygous for the two mutations (inherited in trans). GA, gestational age; NA, not applicable/available; PNDM, permanent neonatal diabetes; TNDM, transient neonatal diabetes. 
